Clinical data | |
---|---|
Trade names | Robaxin, Marbaxin, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682579 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
Drug class | Muscle relaxant[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Liver |
Elimination half-life | 1.14–1.24 hours[3] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C11H15NO5 |
Molar mass | 241.243 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Methocarbamol, sold under the brand name Robaxin among others, is a medication used for short-term musculoskeletal pain.[1][4] It may be used together with rest, physical therapy, and pain medication.[1][8][9] It is less preferred in low back pain.[1] It has limited use for rheumatoid arthritis and cerebral palsy.[1][10] Effects generally begin within half an hour.[1] It is taken by mouth or injection into a vein.[1]
Common side effect include headaches, sleepiness, dizziness.[1][5] Serious side effects may include anaphylaxis, liver problems, confusion, and seizures.[4] Use is not recommended in pregnancy and breastfeeding.[1][4] Use by the elderly is considered high risk.[1] Methocarbamol is a centrally acting muscle relaxant.[1] How it works is unclear, but it does not appear to affect muscles directly.[1]
Methocarbamol was approved for medical use in the United States in 1957.[1] It is available as a generic medication.[1][4] It is relatively inexpensive as of 2016.[11] In 2017, it was the 178th most commonly prescribed medication in the United States, with more than three million prescriptions.[12][13]
References
edit- ^ a b c d e f g h i j k l m n o p "Methocarbamol Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 4 March 2021. Retrieved 8 April 2019.
- ^ "Robaxin-750 - Summary of Product Characteristics (SmPC)". (emc). 8 August 2017. Archived from the original on 29 August 2021. Retrieved 19 April 2020.
- ^ Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G (1990). "Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals". European Journal of Clinical Pharmacology. 39 (2): 193–4. doi:10.1007/BF00280060. PMID 2253675.
- ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1093. ISBN 9780857113382.
- ^ a b "Methocarbamol". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 30 January 2017. PMID 31643609. Archived from the original on 28 August 2021. Retrieved 18 April 2020.
- ^ "Methocarbamol Use During Pregnancy". Drugs.com. 10 April 2020. Archived from the original on 23 January 2021. Retrieved 19 April 2020.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 21 January 2021. Retrieved 8 September 2020.
- ^ "Robaxin- methocarbamol tablet, film coated". DailyMed. 18 July 2019. Archived from the original on 22 October 2020. Retrieved 19 April 2020.
- ^ "Robaxin- methocarbamol injection". DailyMed. 10 December 2018. Archived from the original on 28 August 2021. Retrieved 19 April 2020.
- ^ Richards, Bethan L.; Whittle, Samuel L.; Buchbinder, Rachelle (2012-01-18). "Muscle relaxants for pain management in rheumatoid arthritis". The Cochrane Database of Systematic Reviews. 1: CD008922. doi:10.1002/14651858.CD008922.pub2. ISSN 1469-493X. PMID 22258993.
- ^ Fine, Perry G. (2016). The Hospice Companion: Best Practices for Interdisciplinary Care of Advanced Illness. Oxford University Press. p. PT146. ISBN 978-0-19-045692-4.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Methocarbamol - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.